Liminatus plans to invest up to $500 million in BNB coin

LA PALMA, Calif. - Liminatus Pharma, Inc. (NASDAQ:LIMN), a $226.59 million market cap company whose stock has surged over 56% in the past week according to InvestingPro data, announced Monday plans to establish a subsidiary called American BNB Strategy focused on investing up to $500 million in BNB coin, the native token of the Binance ecosystem.

The preclinical-stage biopharmaceutical company, which develops targeted cancer immunotherapies and currently shows negative earnings of $0.14 per share, said the investment would be deployed in phases as part of a long-term strategic initiative in the cryptocurrency sector. InvestingPro analysis reveals 6 additional key insights about the company’s financial health and growth prospects.

According to the press release statement, Liminatus selected BNB Coin over other digital assets due to its technology, global user base, and features such as Launchpool participation and staking models.

"This is not a short-term speculative initiative, but rather a value driven strategy based on the long-term growth potential and strength of the BNB ecosystem," said Chris Kim, CEO of Liminatus.

The company plans to utilize custody infrastructure provided by Ceffu, an affiliated entity within the BNB ecosystem, for security and operational integrity.

Liminatus emphasized it remains committed to its core business of advancing cancer therapeutics and developing pancreatic cancer diagnostics while expanding into digital assets to support long-term growth.

The initiative is currently undergoing a capital raise process in collaboration with placement agent Digital Offering and remains subject to board approval, regulatory clearance, and market conditions. With the stock’s high volatility and trading at $8.71, significantly above its 52-week low of $4.40, investors can access detailed valuation metrics and real-time analysis through InvestingPro’s comprehensive financial toolkit.

In other recent news, Liminatus Pharma has engaged Digital Offering LLC as its exclusive placement agent to explore potential strategic capital raise options. This move supports the company’s ongoing evaluation of modern financial tools to enhance its capital structure, including the possible use of convertible debentures and equity-linked securities. Additionally, Liminatus Pharma is conducting a strategic review to potentially incorporate regulated digital assets into its treasury management framework. In a separate development, the company has reached a settlement agreement with Alta Partners, exchanging 1 million warrants for 350,000 shares of common stock, with no commission or remuneration involved in the transaction. Furthermore, Liminatus Pharma has expanded its board of directors with the appointment of Philip Lemons and Richard Baek, bringing additional expertise to the company’s governance. These recent developments reflect Liminatus Pharma’s strategic efforts to strengthen its financial position and corporate governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.